Evogene
Business Services · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
13 Gad Feinstein St. Park Rehovot, Rehov...Phone Number
+97289311900Website
www.evogene.comRevenue
<$5 MillionStock Symbol
EVGNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Evogene
Evogene is a computational chemistry company that develops artificial intelligence–driven technologies for the discovery and design of novel small molecules for pharmaceutical and agricultural applications. The company leverages its proprietary AI platform to optimize molecule design, accelerate research and development, and improve the transition of scientific discoveries into practical, commercially viable products through strategic collaborations and internal innovation initiatives.Explore more
Evogene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evogene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Evogene has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Evogene launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Evogene recently announced quarterly report
Evogene, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Evogene has new funding data
Congratulate Masked Content for being promoted to Masked Content at Evogene
Check out if Evogene is spiking on competitors!
Click to see if Evogene had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Evogene
Find more new buyers
Company Profile Activity
Activity Insights
Evogene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Evogene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Evogene.
Evogene financials insights
Gather financial insights about Evogene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$5M
2020
Share Placement
$10M
Evogene Tech Stack
A closer look at the technologies used by Evogene
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Evogene has reported a net loss of approximately $1.8 million for Q2 2026, a decrease of approximately 62% compared to approximately $4.7 million in Q2 2025, while the H1 2026 net loss of approximately $7.7 million remained essentially unchanged from H1 2025.
Earnings, Finance
Earnings
Evogene has reported cash and cash equivalents of approximately $9.3 million as of June 30, 2026, with consolidated cash usage of approximately $2.1 million during Q2 2026 and full year 2026 expected cash usage of approximately $8.5 to $9.5 million.
Earnings, Finance, Financial Operations
Earnings
Evogene has reported net financing expenses of approximately $1.7 million for H1 2026, compared to net financing income of approximately $0.8 million in H1 2025, primarily driven by approximately $3.8 million in financial expenses related to a February 2026 warrant inducement transaction, partially offset by approximately $2.1 million in financing income from the revaluation of warrant liabilities.
Earnings, Finance, Financing & Debt
Person-Based
Partnership, Pharmaceuticals, Corporate Strategy
Evogene News & Media
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nominees, at the September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 25, 2026...Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q2 2026 Earnings Call August 18, 2026 9:00 AM EDTCompany ParticipantsOfer Haviv - CEO, President & DirectorNir NimrodiPolina Ravzin...Evogene Reports Second Quarter and First Half 2026 Financial Results
Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs Cash burn expected to decline to approximately $8.5–$9.5 million in 2026,...Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Evogene
Sign Up For FreeTo access detailed company insights
Evogene is a computational chemistry company that develops artificial intelligence–driven technologies for the discovery and design of novel small molecules for pharmaceutical and agricultural applications. The company leverages its proprietary AI platform to optimize molecule design, accelerate research and development, and improve the transition... Read More
